


Blebmaker: advancing glaucoma outcomes



OVERVIEW

Blebmaker is a first-in-class ocular implant designed to prevent bleb collapse by providing mechanical support and releasing anti-inflammatory drugs.

This innovation enhances the success of filtration surgeries, simplifies recovery and reduces the economic burden associated with glaucoma treatment.

PROJECT

Sector: Ophthalmology, Glaucoma

R&D direction:

Research group for the enhancement of glaucoma surgeries outcomes

Stage of development: TRL3

Scientific leader: Dr. Jordi Loscos

PRODUCT

Indications: Glaucoma

Mechanism of action:

Prevents the collapse of the filtration blister by avoiding fibrosis and inflammation

Market Size: €8B in 2023

IP PROTECTION

Patent filed

OPPORTUNITY

License out

Spin-off incorporation

Co-development

NEED

Glaucoma is the leading cause of irreversible blindness, affecting 76M people in 2022 and expected to rise to 111M in 2040. Currently, 90% of surgeries are based on the creation of a filtration bleb which redirects the aqueous humor outside the eye, reducing intraocular pressure. Nonetheless, after a couple of years, the bleb collapses and 50% of the patients² need additional surgeries which are more invasive and can have complications such as hypotony and gout³.

SOLUTION

The Blebmaker is designed to prevent filtration bleb collapse by forming a dome-like structure between the conjunctiva and sclera. It maintains optimal bleb dimensions, ensures proper fluid flow and avoids layer adherence. Additionally, it delivers anti-inflammatory drugs to enhance long-term therapeutic effectiveness.

KEY ADVANTAGES

- ✓ Prevents bleb collapse: maintains optimal bleb dimensions and flow, reducing the risk of collapse.
- ✓ Reduces fibrosis: minimizes excessive scar tissue formation that can obstruct the bleb.
- ✓ Drug delivery: administers anti-inflammatory medication directly, enhancing long-term effectiveness.

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit